| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 4, 2024 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/27/2025 | $7.00 | Overweight | Analyst |
| 12/6/2024 | $7.00 | Buy | Jefferies |
| 6/13/2024 | $8.00 | Outperform | Robert W. Baird |
| 10/13/2023 | $4.00 | Buy | BTIG Research |
| 8/12/2022 | $4.00 | Overweight | Cantor Fitzgerald |
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) Cash of $69.8 million as of December 31, 2024, expected to fund operations into 2027 LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2024, and provided recent corporate highlights. "2024 was a
LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 12, 2025, at 8:40 am ET / 1:40 pm GMT. A live audio webcast of the fireside chat can be accessed through the Investors section of the Company's website at www.mereobiopharma.com/investors. An archived replay of the webcast will be available on the Company's website for two weeks following the live event. About Mereo Bi
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease, receives positive EMA opinion on European Orphan Designation Application; European Commission expected to issue final decision in first quarter 2025 LONDON, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on its lead clinical programs, setrusumab, a monoclonal antibody in Phase 3 clinical development for the treatment of Osteogenesis Imperfecta
LONDON and REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Dr. Abdul Mullick to the Company's Board of Directors, effective immediately. Dr. Mullick joins Mereo's Board with over 20 years of experience in the pharmaceutical industry in senior leadership positions across multiple therapeutic areas and geographies, including in rare diseases. "We are very excited to welcome Abdul to the Board at such a pivotal time for the Company," said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo. "His e
LONDON and REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Anne Hyland to the Company's Board of Directors, effective immediately. Ms. Hyland has also been appointed to serve on the Audit and Risk Committee of the Board. Ms. Hyland joins Mereo's Board with over 30 years of financial experience in both private and public companies in the biopharmaceutical space. "We are very excited to welcome someone with Anne's level of operational and board experience to our Board," said Dr. Denise Scots-Knight, C
LONDON and REDWOOD CITY, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Pierre Jacquet, M.D., Ph.D to the Company's Board of Directors, effective September 20, 2021. Dr. Jacquet joins Mereo's Board with over two decades of multidisciplinary experience in the life science industry, including corporate strategy, M&A advisory and value management. "We are delighted to have Pierre joining our board of directors at such an exciting and important time for the Company," said Dr. Denise Scots-Knight, Chief Executive Off
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) Cash of $69.8 million as of December 31, 2024, expected to fund operations into 2027 LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2024, and provided recent corporate highlights. "2024 was a
LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $48.7 million as of March 31, 2024 and continues to expect this to fund its operations into 2026. "2024 is off to an exciting start following the completion of enrollment by our partner Ultragenyx in both the Orbit and Cosmic studies of setrusumab in Osteogenesis Imperfecta (OI) along with the continued advancement of the pre-laun
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively Partnering discussions for alvelestat progressing with plans to initiate Phase 3 with a partner around the end of 2024 Cash of $57.4 million as of December 31, 2023 expected to fund operations into 2026 LONDON, March 27, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2023, and provided an update on recent co
4 - Mereo BioPharma Group plc (0001719714) (Issuer)
4 - Mereo BioPharma Group plc (0001719714) (Issuer)
4 - Mereo BioPharma Group plc (0001719714) (Issuer)
10-K - Mereo BioPharma Group plc (0001719714) (Filer)
8-K - Mereo BioPharma Group plc (0001719714) (Filer)
SCHEDULE 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)
SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)
SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)
SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)
Analyst initiated coverage of Mereo BioPharma with a rating of Overweight and set a new price target of $7.00
Jefferies initiated coverage of Mereo BioPharma with a rating of Buy and set a new price target of $7.00
Robert W. Baird initiated coverage of Mereo BioPharma with a rating of Outperform and set a new price target of $8.00